G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab-Reference-Cited by-同舟云学术

G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab

Published:2015-12-10 Issue:5 Volume:37 Page:6823-6830
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumor Biol.

Author:

Fiala Ondrej,Buchler Tomas,Mohelnikova-Duchonova Beatrice,Melichar Bohuslav,Matejka Vit Martin,Holubec Lubos,Kulhankova Jana,Bortlicek Zbynek,Bartouskova Marie,Liska Vaclav,Topolcan Ondrej,Sedivcova Monika,Finek Jindrich

Funder

Ministry of Education Youth and Sports of the Czech Republic

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13277-015-4523-7.pdf

Reference42 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;250:2335–42.

3. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival in patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706–12.

4. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

5. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Investigators of the BRiTE study clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14:862–70.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer;Signal Transduction and Targeted Therapy;2024-08-21

2. Transglutaminase 2 serves as a pathogenic hub gene of KRAS mutant colon cancer based on integrated analysis;World Journal of Gastrointestinal Oncology;2024-05-15

3. KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner;Journal of Translational Medicine;2023-10-31

4. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review;The Oncologist;2023-07-11

5. Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer;Journal of Personalized Medicine;2023-06-26